David J Riese Ii

List of Publications by Year
in descending order

50	3,805	236925	206112
papers	citations	25 h-index	48 g-index

53	53	53	4346
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Specificity within the EGF family/ErbB receptor family signaling network. BioEssays, 1998, 20, 41-48.	2.5	695
2	The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family. Molecular and Cellular Biology, 1995, 15, 5770-5776.	2.3	364
3	Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature, 1997, 387, 509-512.	27.8	272
4	Functional selectivity of EGF family peptide growth factors: Implications for cancer. , 2009, 122, 1-8.		225
5	The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-Î±, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4. Journal of Biological Chemistry, 1996, 271, 20047-20052.	3.4	146
6	The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer. Frontiers in Pharmacology, 2020, 11, 574667.	3.5	143
7	Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. Cancer Research, 2007, 67, 7319-7326.	0.9	136
8	Epiregulin: Roles in normal physiology and cancer. Seminars in Cell and Developmental Biology, 2014, 28, 49-56.	5.0	135
9	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment, 2009, 114, 263-75.	2.5	129
10	EGFR signaling in breast cancer: Bad to the bone. Seminars in Cell and Developmental Biology, 2010, 21, 951-960.	5.0	129
11	c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Molecular Cancer Research, 2002, 1, 79-87.	3.4	113
12	Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer. Journal of Biological Chemistry, 2000, 275, 19803-19807.	3.4	104
13	EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors, 2012, 30, 107-116.	1.7	103
14	Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2. Journal of Biological Chemistry, 1998, 273, 11288-11294.	3.4	91
15	Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells. Journal of Biological Chemistry, 1997, 272, 3330-3335.	3.4	88
16	Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. BioEssays, 2007, 29, 558-565.	2.5	83
17	Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene, 2002, 21, 8442-8452.	5.9	81
18	Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cellular Signalling, 2009, 21, 212-219.	3.6	64

#	Article	IF	Citations
19	A high throughput, interactive imaging, brightâ€field wound healing assay. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 227-232.	1.5	51
20	Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Research and Treatment, 2008, 110, 493-505.	2.5	49
21	Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. Human Molecular Genetics, 2009, 18, 4478-4491.	2.9	49
22	Design, Synthesis, and Biological Evaluation of a Series of Lavendustin A Analogues That Inhibit EGFR and Syk Tyrosine Kinases, as Well as Tubulin Polymerization. Journal of Medicinal Chemistry, 2001, 44, 441-452.	6.4	46
23	A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Letters, 2003, 192, 67-74.	7.2	44
24	Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12480-12484.	7.1	41
25	Anilinodialkoxyquinazolines:â€‰ Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes. Journal of Medicinal Chemistry, 2005, 48, 7445-7456.	6.4	33
26	ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. Genes and Cancer, 2011, 2, 792-804.	1.9	33
27	The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Pharmacological Reviews, 2022, 74, 18-47.	16.0	31
28	Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene, 2004, 23, 883-893.	5.9	28
29	Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Experimental Cell Research, 2011, 317, 392-404.	2.6	27
30	Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochemical and Biophysical Research Communications, 2006, 349, 372-382.	2.1	26
31	Phosphorylation of ErbB4 on Tyrosine 1056 Is Critical for ErbB4 Coupling to Inhibition of Colony Formation by Human Mammary Cell Lines. Oncology Research, 2006, 16, 179-193.	1.5	24
32	Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug discovery?. Expert Opinion on Drug Discovery, 2011, 6, 185-193.	5.0	22
33	Autocrine-Derived Epidermal Growth Factor Receptor Ligands Contribute to Recruitment of Tumor-Associated Macrophage and Growth of Basal Breast Cancer Cells In Vivo. Oncology Research, 2013, 20, 303-317.	1.5	19
34	Reconstitution of Amphiregulinâ€“Epidermal Growth Factor Receptor Signaling in Lung Squamous Cell Carcinomas Activates PTHrP Gene Expression and Contributes to Cancer-Mediated Diseases of the Bone. Molecular Cancer Research, 2009, 7, 1714-1728.	3.4	18
35	Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 247-56.	0.8	18
36	ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cellular Signalling, 2002, 14, 793-798.	3.6	17

#	Article	IF	Citations
37	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2Î² and agonist-independent coupling with downstream signalling events. Biochemical Journal, 2006, 396, 79-88.	3.7	16
38	Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochemical and Biophysical Research Communications, 2007, 364, 351-357.	2.1	15
39	Comparison of the enantiomers of (Â±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors. European Neuropsychopharmacology, 2009, 19, 138-146.	0.7	14
40	At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology / the Society of the Nippon Dental University, 2012, 100, 109-129.	1.9	14
41	Estrogen receptor-Î±, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. Journal of Veterinary Science, 2017, 18, 149.	1.3	14
42	EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer: Targets and Therapy, 2009, 1, 31.	1.8	13
43	secErbB4-26/549 Antagonizes Ligand-Induced ErbB4 Tyrosine Phosphorylation. Oncology Research, 2004, 14, 589-602.	1.5	13
44	Phe45 of NRG2Î² is critical for the affinity of NRG2Î² for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2Î². Growth Factors, 2005, 23, 273-283.	1.7	8
45	The Q43L mutant of neuregulin 2Î² is a pan-ErbB receptor antagonist. Biochemical Journal, 2012, 443, 133-144.	3.7	7
46	The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. Growth Factors, 2007, 25, 329-333.	1.7	4
47	Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Protein Expression and Purification, 2016, 125, 26-33.	1.3	3
48	Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. PLoS ONE, 2020, 15, e0243901.	2.5	3
49	Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. Journal of Cancer Research and Therapeutic Oncology, 2013, 1, 10.	0.0	3
50	Abstract 814: Identification of ERBB4 mutant alleles that function as tumor drivers. , 2021, , .		0